Literature DB >> 33788385

Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients.

Jing Jin1, Vinay Kandula2, Robin E Miller3.   

Abstract

PURPOSE: This study aimed to confirm the correlation between sickle cell disease (SCD) genotype and retinal damage identified by spectral-domain optical coherence tomography (SD-OCT), and examine a potential link between hypoxic ischemic injury in the retina and brain.
METHODS: In this prospective, observational case series, 117 patients (56 males) aged 5-20 years with SCD (36 SC, 68 SS, eight Sβ+ thalassemia, five Sβ0 thalassemia) underwent ophthalmologic examination including funduscopy and SD-OCT imaging. Comparison of SCD genotypes and association between ocular findings and cerebrovascular disease (CVD) in subjects with SS/Sβ0 genotype were investigated.
RESULTS: Visual acuity ranged from 20/20 to 20/40. On funduscopic exam, 16 of 117 (13.7%) had retinopathy; 69 of 117 (59.0%) showed inner retina thinning on SD-OCT. Patients with SS/Sβ0 showed a higher frequency of sickle cell retinopathy (SCR) change (68.5% vs. 47.2%), bilateral SCR (49.9% vs. 25.0%), and foveal involvement (15.1% vs. 0) than the SC genotype. While funduscopic findings in our cohort with SS/Sβ0 genotype showed no correlation with CVD, 20 of 21 patients with CVD had abnormal SD-OCT. Elevated reticulocyte percentage and aspartate aminotransferase are associated with SD-OCT changes and CVD.
CONCLUSIONS: SD-OCT was better than funduscopy in detecting retinal changes, higher frequency, and more extensive retinal changes in the more severe SCD genotypes SS and Sβ0 as compared with SC. The correlation between abnormal SD-OCT and CVD strongly suggests that retinal exam using SD-OCT may aid in detection and monitoring SCD-related CVD. Retinopathy may be another component of the hemolytic subphenotype of SCD.
© 2021 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

Entities:  

Keywords:  OCT; cerebrovascular disease; sickle cell retinopathy; silent cerebral infarct

Mesh:

Year:  2021        PMID: 33788385      PMCID: PMC8638774          DOI: 10.1002/pbc.29028

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.838


  45 in total

1.  The number of people with sickle-cell disease in the United States: national and state estimates.

Authors:  David C Brousseau; Julie A Panepinto; Mark Nimmer; Raymond G Hoffmann
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

2.  Structural and functional correlation in sickle cell retinopathy using spectral-domain optical coherence tomography and scanning laser ophthalmoscope microperimetry.

Authors:  Clement C Chow; Mohamed A Genead; Anastasios Anastasakis; Felix Y Chau; Gerald A Fishman; Jennifer I Lim
Journal:  Am J Ophthalmol       Date:  2011-07-02       Impact factor: 5.258

3.  Risk factors for proliferative sickle retinopathy.

Authors:  P D Fox; D T Dunn; J S Morris; G R Serjeant
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

4.  Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.

Authors:  Michael R DeBaun; Mae Gordon; Robert C McKinstry; Michael J Noetzel; Desiree A White; Sharada A Sarnaik; Emily R Meier; Thomas H Howard; Suvankar Majumdar; Baba P D Inusa; Paul T Telfer; Melanie Kirby-Allen; Timothy L McCavit; Annie Kamdem; Gladstone Airewele; Gerald M Woods; Brian Berman; Julie A Panepinto; Beng R Fuh; Janet L Kwiatkowski; Allison A King; Jason M Fixler; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Natalia Dixon; Corina E Gonzalez; Karen A Kalinyak; Charles T Quinn; John J Strouse; J Philip Miller; Harold Lehmann; Michael A Kraut; William S Ball; Deborah Hirtz; James F Casella
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

Review 5.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Pain in sickle cell disease. Rates and risk factors.

Authors:  O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

7.  Spectral domain optical coherence tomography in patients with sickle cell disease.

Authors:  Raeba Mathew; Rinoza Bafiq; Jayashree Ramu; Elizabeth Pearce; Matthew Richardson; Emma Drasar; Swee Lay Thein; Sobha Sivaprasad
Journal:  Br J Ophthalmol       Date:  2015-01-16       Impact factor: 4.638

8.  Incidence of ocular abnormalities in patients with sickle hemoglobinopathies.

Authors:  T R Friberg; C M Young; P F Milner
Journal:  Ann Ophthalmol       Date:  1986-04

9.  Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid.

Authors:  Sahng Yeon Kim; Carmen Mocanu; D Scott Mcleod; Imran A Bhutto; Carol Merges; Mark Eid; Patrick Tong; Gerard A Lutty
Journal:  Exp Eye Res       Date:  2003-10       Impact factor: 3.467

10.  Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.

Authors:  Kathleen Jee; Murilo Rodrigues; Fabiana Kashiwabuchi; Brooks P Applewhite; Ian Han; Gerard Lutty; Morton F Goldberg; Gregg L Semenza; Silvia Montaner; Akrit Sodhi
Journal:  PLoS One       Date:  2017-08-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.